Chronic Lymphocytic Leukemia

In a video interview, Matthew Cortese, MD, MPH, discusses strategies to combat infections in CLL patients.

In a video interview, Matthew Cortese, MD, MPH, discusses advances in treatments for relapse/refractory CLL.

In a video interview, Matthew Cortese, MD, MPH, discusses how to approach initial treatment of CLL.

Adults with chronic lymphocytic leukemia under active surveillance had a significantly longer treatment-free survival period if they took vitamin D supplements, results from a retrospective study published in Blood Advances showed.

Allen S. Ho, MD, did not wait to promote active surveillance when he started practicing medicine a decade ago.

Individuals with low-risk chronic lymphocytic leukemia who exhibit no symptoms may no longer require specialized follow-up, according to study data published in Blood Advances.

The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of certain patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab was well tolerated and showed promising efficacy in patients with relapsed or refractory chronic lymphocytic leukemia, according to data presented at ASH Annual Meeting.

Early treatment with lenalidomide resulted in a prolonged time to subsequent therapy in patients with high-risk chronic lymphocytic leukemia, according to extended follow-up data presented at ASH Annual Meeting and Exposition.

Combination ibrutinib and venetoclax for first-line treatment yielded a 5-year PFS of 90.1% and 5-year OS of 95.6% in 120 patients with chronic lymphocytic leukemia, according to long-term follow-up data presented at ASH Annual Meeting.